Can proliferation signal inhibitor-induced Tregs really reflect transplantation tolerance in clinical solid organ transplantation?
Exploring new immunosuppressive strategies inducing donor-specific hyporesponsiveness is a great challenge in transplantation. For this purpose, monitoring the alloimmune response is a critical step to carrying out protolerogenic immunosuppressive protocols. Regulatory T cells (Tregs), known as controlling various immune responses, were found to play an important part in allograft transplant tolerance. It is said that Rapamycin (RAPA), one of the proliferation signal inhibitors (PSIs), could achieve true tolerance through the induction of Tregs in clinical trials. Can PSI-induced Tregs in peripheral blood mononuclear cells (PBMC) really reflect transplantation tolerance in clinical solid organ transplantation?
Li
Suping
S
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, PR China.
Kuang
Anren
A
Huang
Rui
R
D000818:Animals; D002986:Clinical Trials as Topic; D000068338:Everolimus; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016377:Organ Transplantation; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology; D023001:Transplantation Tolerance / Q000187:drug effects* / Q000276:immunology
D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus